دورية أكاديمية
CD105 expression in cancer-associated fibroblasts: a biomarker for bone metastasis in early invasive ductal breast cancer patients.
| العنوان: | CD105 expression in cancer-associated fibroblasts: a biomarker for bone metastasis in early invasive ductal breast cancer patients. |
|---|---|
| المؤلفون: | Giorello MB; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Martinez LM; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, United States., Borzone FR; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Padin MDR; Departamento de Anatomía Patológica, Hospital Italiano, Buenos Aires, Argentina., Mora MF; Departamento de Anatomía Patológica, Hospital Italiano, Buenos Aires, Argentina., Sevic I; Laboratorio de Microambiente Tumoral, Centro de Investigaciones Basicas y Aplicadas (CIBA), Junín, Argentina., Alaniz L; Laboratorio de Microambiente Tumoral, Centro de Investigaciones Basicas y Aplicadas (CIBA), Junín, Argentina., Calcagno ML; Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina., García-Rivello H; Departamento de Anatomía Patológica, Hospital Italiano, Buenos Aires, Argentina., Wernicke A; Departamento de Anatomía Patológica, Hospital Italiano, Buenos Aires, Argentina., Labovsky V; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina., Chasseing NA; Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina. |
| المصدر: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2023 Aug 31; Vol. 11, pp. 1250869. Date of Electronic Publication: 2023 Aug 31 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| مستخلص: | Introduction: Bone metastasis is one of the causes that mainly decrease survival in patients with advanced breast cancer. Therefore, it is essential to find prognostic markers for the occurrence of this type of metastasis during the early stage of the disease. Currently, cancer-associated fibroblasts, which represent 80% of the fibroblasts present in the tumor microenvironment, are an interesting target for studying new biomarkers and developing alternative therapies. This study evaluated the prognostic significance of the CD105 expression in cancer-associated fibroblasts in early breast cancer patients. Methods: Immunohistochemistry was used to assess CD105 expression in invasive ductal breast carcinomas (n = 342), analyzing its association with clinical and pathological characteristics. Results: High CD105 expression in cancer-associated fibroblasts was associated with an increased risk of metastatic occurrence ( p = 0.0003), particularly bone metastasis ( p = 0.0005). Furthermore, high CD105 expression was associated with shorter metastasis-free survival, bone metastasis-free survival, and overall survival ( p = 0.0002, 0.0006, and 0.0002, respectively). CD105 expression also constituted an independent prognostic factor for metastasis-free survival, bone metastasis-free survival, and overall survival ( p = 0.0003, 0.0006, and 0.0001, respectively). Discussion: The high CD105 expression in cancer-associated fibroblasts is an independent prognostic marker for bone metastasis in early breast cancer patients. Therefore, the evaluation of CD105(+) CAFs could be crucial to stratify BCPs based on their individual risk profile for the development of BM, enhancing treatment strategies and outcomes. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Giorello, Martinez, Borzone, Padin, Mora, Sevic, Alaniz, Calcagno, García-Rivello, Wernicke, Labovsky and Chasseing.) |
| References: | Pathol Res Pract. 2020 May;216(5):152915. (PMID: 32146002) Clin Cancer Res. 2004 Sep 1;10(17):5815-9. (PMID: 15355911) Cell Adh Migr. 2012 May-Jun;6(3):249-60. (PMID: 22568982) Curr Med Chem. 2018;25(29):3414-3434. (PMID: 29521203) PLoS One. 2015 Mar 24;10(3):e0121421. (PMID: 25803686) Br J Cancer. 1957 Sep;11(3):359-77. (PMID: 13499785) JAMA Netw Open. 2020 Oct 1;3(10):e2018790. (PMID: 33034638) Cancers (Basel). 2021 Aug 26;13(17):. (PMID: 34503118) Exp Ther Med. 2012 Aug;4(2):231-236. (PMID: 23139713) Int J Cancer. 1988 May 15;41(5):707-12. (PMID: 2835323) J Biomed Sci. 2023 Jan 4;30(1):1. (PMID: 36600243) Cancer Res. 2012 Jun 1;72(11):2879-88. (PMID: 22496457) Clin Breast Cancer. 2018 Feb;18(1):e123-e133. (PMID: 28927692) Nat Rev Cancer. 2006 May;6(5):392-401. (PMID: 16572188) Breast Cancer Res. 2001;3(3):143-5. (PMID: 11305947) J Clin Invest. 2018 Jan 2;128(1):16-25. (PMID: 29293090) Breast Cancer Res Treat. 2012 Jan;131(2):401-11. (PMID: 21344235) Arch Iran Med. 2022 Sep 01;25(9):609-616. (PMID: 37543886) Breast Cancer Res Treat. 2011 Feb;125(3):687-96. (PMID: 20361254) Nature. 2007 Oct 4;449(7162):557-63. (PMID: 17914389) Int J Mol Sci. 2021 Oct 27;22(21):. (PMID: 34769066) Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877) J Pathol. 2019 Sep;249(1):6-18. (PMID: 31095738) Clin Cancer Res. 2007 Sep 1;13(17):5020-7. (PMID: 17785552) Mol Aspects Med. 2014 Oct;39:3-32. (PMID: 23994756) Crit Rev Oncol Hematol. 2016 Jan;97:303-11. (PMID: 26467073) Int J Oncol. 2004 May;24(5):1197-204. (PMID: 15067342) Cells. 2020 Jun 02;9(6):. (PMID: 32498363) Int J Mol Sci. 2020 Nov 15;21(22):. (PMID: 33203195) J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):135-155. (PMID: 33398516) Ann Oncol. 2005;16 Suppl 1:i7-9. (PMID: 15888763) Cancer Cell. 2023 Mar 13;41(3):374-403. (PMID: 36917948) Oncotarget. 2016 Nov 29;7(48):79688-79705. (PMID: 27806311) J Exp Med. 2018 Dec 3;215(12):3075-3093. (PMID: 30470719) Breast Cancer Res Treat. 2010 Jul;122(1):27-34. (PMID: 20454925) Pathol Res Pract. 2011 Dec 15;207(12):739-46. (PMID: 22051146) Int J Mol Sci. 2021 Mar 20;22(6):. (PMID: 33804796) Ann Surg. 1981 Nov;194(5):585-91. (PMID: 7294929) Biomaterials. 2020 Jul;247:119975. (PMID: 32278213) Clin Exp Metastasis. 2012 Oct;29(7):663-72. (PMID: 22684404) Medicina (B Aires). 2011;71(1):15-21. (PMID: 21296715) Breast. 2022 Mar;62 Suppl 1:S3-S6. (PMID: 35219542) Exp Cell Res. 2016 May 15;344(1):53-66. (PMID: 27112989) J Cell Physiol. 2020 May;235(5):4268-4278. (PMID: 31608996) Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23. (PMID: 23970019) Clin Breast Cancer. 2015 Feb;15(1):e13-21. (PMID: 25044301) Mod Pathol. 2003 Feb;16(2):99-107. (PMID: 12591961) Semin Cancer Biol. 2020 May;62:166-181. (PMID: 31415910) Front Cell Dev Biol. 2023 Jan 30;11:1089068. (PMID: 36793444) Int J Cancer. 2021 May 1;148(9):2289-2303. (PMID: 33252836) |
| فهرسة مساهمة: | Keywords: CD105; bone metastasis; breast cancer; cancer-associated fibroblasts; prognosis factor |
| تواريخ الأحداث: | Date Created: 20230918 Latest Revision: 20230919 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10501720 |
| DOI: | 10.3389/fcell.2023.1250869 |
| PMID: | 37719885 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2023.1250869 |